Therapeutic | Evolocumab |
Target | PCSK9 |
Heavy Chain | EVQLVQSGAEVKKPGASVKVSCKASGYTLTSYGISWVRQAPGQGLEWMGWVSFYNGNTNYAQKLQGRGTMTTDPSTSTAYMELRSLRSDDTAVYYCARGYGMDVWGQGTTVTVSS |
Light Chain | ESALTQPASVSGSPGQSITISCTGTSSDVGGYNSVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYTSTSMVFGGGTKLTVL |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G2 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | Abgenix XenoMouse |
INN Year Proposed | 2012 |
INN Year Recommended | 2013 |
Companies Involved | Amgen, Amgen Astellas BioPharma, University Hospital Inselspital |
Conditions Approved | Coronary disorders, Hypercholesterolaemia, Hyperlipoproteinaemia type IIa, Myocardial infarction, Stroke |
Conditions Active | Hyperlipidaemia |
Conditions Discontinued | na |
Notes |